Research:
The
goal of my laboratory is to discover, develop and improve novel gene therapy
for treating malignancy and other severe genetic diseases. To realize our
goal, we are conducting studies in the following areas: 1) developing novel
intramuscular electroporation-based therapies for treating residual systemic
malignancy; 2) developing effective local tumor electroporation therapy
for eradicating heavy-load tumors; 3) developing chemogene therapy for treating
tumors; 4) developing tumor-anchoring or homing gene therapy for reducing
toxicity; and 5) understanding the molecular mechanism of tumor growth inhibition
mediated by electroporation gene therapy in combination with chemotherapy.
These research projects are supported by NCI/NIH and NIDCR/NIH.
Recent
Publications:
Li,
S, M Wilkinson, X Xia, M David, L Xu, A Purkel-Sutton and A Bhardwaj (2005).
Induction of IFN-regulated factors and antitumoral surveillance by transfected
placebo plasmid DNA. Molecular Therapy. 11(1):112-119
Li,
S et al. (2005) Administration route- and immune cell activation-dependent
tumor eradication by IL-12 electrotransfer Molecular Therapy 12(5):942-949.
Torrero,
M, W Henk and S Li (2006). Regression of highrade
malignancy in mice by bleomycin and Interleukin-12. electrochemogenetherapy.
Clinical Cancer Research 12(1):257-263
Torrero M, Xia X, Henk W, Yu S and S Li (2006) Stat1 deficiency in the host
enhances IL-12-mediated inhibition of tumor growth Cancer Research 66(8):4461-4467
Liu
J, Xia X, Torrero M, Barrett R, Craig R, Shillitoe EJ and S Li (2006) The
Mechanism of Exogenous B7.1-Enhanced IL-12-Mediated Complete Regression
of Tumors by a Single Electroporation Delivery. International Journal of
Cancer (in press)
|